Lacosamide-induced sinus node dysfunction followed by severe agranulocytosis

Lacosamide-induced sinus node dysfunction followed by severe agranulocytosis

Abstract Background Lacosamide (LCM) is the antiepileptic drug approved by the U.S. Food and Drug Administration in 2008 that facilitates slow activation of the voltage-gated sodium channels. Neutropenia and cardiac events including sinus node dysfunction (SND) and atrioventricular block have been p...

Full description

Bibliographic Details
Main Authors: Makoto Shibata, Reona Hoshino, Chisato Shimizu, Masayuki Sato, Natsumi Furuta, Yoshio Ikeda
Format: Article
Language:English
Published: BMC 2021-06-01
Series:BMC Neurology
Subjects:
Lacosamide
Neutropenia
Agranulocytosis
Sinus node dysfunction
Adverse effects
Online Access:https://doi.org/10.1186/s12883-021-02253-1

Internet

https://doi.org/10.1186/s12883-021-02253-1

Similar Items